Clinical News

Pre-Pregnancy Obesity Potentially Linked to Increased Risk of AD in Infants

4 hours ago

By Armand Butera

Investigators added that this risk might possibly be through intrauterine effects, while associations with wheezing might be confounded by familial clustering factors.

Controlling Chronic Kidney Disease in Type 2 Diabetes

9 hours ago

By Jennifer B. Green, MD

Thought leaders discuss recent advances in treatments for patients with type 2 diabetes with chronic kidney disease.

3 Things Primary Care Providers Need to Know About Continuous Glucose Monitoring Technology

9 hours ago

By Aaron King, MD

Type 2 Diabetes: SGLT2 Inhibitors and GLP-1 Receptor Agonists

9 hours ago

By Jennifer B. Green, MD

Dennis Bruemmer, MD, PhD, and Jennifer B. Green, MD, have a conversation about the use of SGLT2 inhibitors and GLP1 receptor agonists in treating type 2 diabetes.

CaFFR Guided Revascularization Show Reduced MACE Risk in Diabetic Patients with CAD

9 hours ago

By Connor Iapoce

Patients considered adherent to caFFR had a significantly lower risk of MACE, compared to non-adherent patients (adjusted hazard ratio, 0.33).

José-Alain Sahel, MD: Safety, Efficacy of Optogenetic Treatment for Retinitis Pigmentosa

November 19, 2021

By Connor Iapoce

At AAO 2021, Dr. Sahel discussed the findings of the PIONEER trial on the combination of an optogenetics device and gene therapy in treatment of RP.

Robert L. Avery, MD Highlights Results on RGX-314 For the Treatment Of Wet AMD

November 17, 2021

By Connor Iapoce

Dr. Avery discusses the positive results of RGX-314 gene therapy, noting dramatic reduction in need for therapy, with stable vision and good thickness results

Dilsher S. Dhoot, MD: Efficacy of Brolucizumab in Treatment of Diabetic Macular Edema

November 16, 2021

By Connor Iapoce

Dr. Dhoot discusses data on visual acuity from the phase 3 KESTREL and KITE trials, comparing brolucizumab to aflibercept at 52 weeks.

Abrocitinib Dosing Effective in Atopic Dermatitis Management

November 16, 2021

By Armand Butera

Investigators said that patient-reported outcomes from the 2 abrocitinib groups showed greater efficacy than the dupilumab and placebo groups.